Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04942054 · ClinicalTrials.gov registry record · Phase 1
A Study in Patients With Advanced Breast Cancer
A Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04942054: Clinical Trial Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.
NCT04942054 is a Phase 1 study that was terminated before completion, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04942054, a Phase 1 study, was terminated before completion, sponsored by Sun Pharma Advanced Research Company Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
A Phase 1, Open label, Dose escalation and Dose expansion study of SCO-120 in HR +ve HER2-ve advanced/ metastatic breast cancer (MBC) patients to evalaute the safety, tolerability and prelimnary efficacy. Initial part with dose escalation is to determine the MTD and RP2D, and PK and PD characterisation. RP2D will be further evalauted for prelimnary efficacy in MBC patients with tretament failure on Aromatase Inhibitor/Fulvestrant/CDK4-6 inhibitors with or with out ESR1 mutation.
Interventions
- DRUG Part 1
- DRUG Part 2
- DRUG Part 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-05-20 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 1 |
Why NCT04942054 stopped before completion
NCT04942054 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 3 interventions - of which Part 1 is the first listed.
NCT04942054 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04942054 about?
NCT04942054 is a clinical study titled "A Study in Patients With Advanced Breast Cancer". A Phase 1, Open label, Dose escalation and Dose expansion study of SCO-120 in HR +ve HER2-ve advanced/ metastatic breast cancer (MBC) patients to evalaute the safety, tolerability and prelimnary efficacy. Initial part with dose escalation is to determine the MTD and RP2D, and PK and PD characterisat...
What is the current status of trial NCT04942054?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-05-20. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT04942054?
The interventions under investigation include: Part 1 (DRUG), Part 2 (DRUG), Part 3 (DRUG).
Who is sponsoring clinical trial NCT04942054?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04942054's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI